RISalud-ANDALUCÍA
Not a member yet
18682 research outputs found
Sort by
Vol. 29, nº 47. VIH/SIDA en Andalucía. Año 2022.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 46/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “VIH/SIDA en Andalucía. Año 2022”, de “Cristina Jiménez Biedma, Isabel Mª Vázquez Rincón, Nicola Lorusso. Juan Carlos Carmona Lagares”.Ye
Identification of SYNJ1 in a Complex Case of Juvenile Parkinsonism Using a Multiomics Approach.
No full textThis study aimed to elucidate the genetic causes underlying the juvenile parkinsonism (JP) diagnosed in a girl with several family members diagnosed with spinocerebellar ataxia type 2 (SCA2). To achieve this, whole-exome sequencing, analysis of CAG repeats, RNA sequencing analysis on fibroblasts, and metabolite identification were performed. As a result, a homozygous missense mutation SNP T>C (rs2254562) in synaptojamin 1 (SYNJ1), which has been implicated in the regulation of membrane trafficking in the synaptic vesicles, was identified. Additionally, we observed overexpression of L1 cell adhesion molecule (L1CAM), Cdc37, GPX1, and GPX4 and lower expression of ceruloplasmin in the patient compared to the control. We also found changes in sphingolipid, inositol, and inositol phosphate metabolism. These findings help to clarify the mechanisms of JP and suggest that the etiology of JP in the patient may be multifactorial. This is the first report of the rs2254562 mutation in the SYNJ gene identified in a JP patient with seizures and cognitive impairment.This research was funded by Fundación Mutua Madrileña, Spain (XIII Call on Research Grants 2016), reference number AP163052016.Ye
Protocolo andaluz para la actuación sanitaria ante la violencia de género: 2024.
No full textColaboración especial de Flor Torres Porras, Fiscal Delegada de Violencia sobre la MujerDocumento que proporciona pautas de actuación homogéneas ante la violencia contra las mujeres a las y los profesionales de ámbito sanitario, mediante la actualización del conocimiento, basado en la experiencia y la evidencia científica de los últimos años. Es importante resaltar que el Protocolo que presentamos incorpora como víctimas directas de la violencia de género a los y a las menores de edad convivientes.N
Vol. 29, nº 18. Hepatitis A en Andalucía, 2017-2023. Análisis descriptivo
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 17/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “Hepatitis A en Andalucía, 2017-2023. Análisis descriptivo”, de “Paloma Rodríguez Baleato, Alba Santos Pérez, Cristina Jiménez Biedma, Clara León Cañadilla”.Ye
Vol. 29, nº 19. Participación de Andalucía en EU JAMRAI 2, segunda acción conjunta europea sobre resistencia a los antimicrobianos e infecciones relacionadas con la asistencia sanitaria
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 18/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “Participación de Andalucía en EU JAMRAI 2, segunda acción conjunta europea sobre resistencia a los antimicrobianos e infecciones relacionadas con la asistencia sanitaria”, de “José Luis Trillo Contreras, María Núñez Núñez, Rocío Fernández Urrusuno”.Ye
Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study
No full textBackground: Cosibelimab is a high-affinity, fully human monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1) and blocks its interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors to restore an anti-tumor immune response. Cosibelimab also has a functional Fc domain capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) as an additional mechanism of anti-tumor immunity. Efficacy and safety data from a pivotal study (NCT03212404) supported a biologics license application for cosibelimab for the treatment of patients (pts) with advanced CSCC (metastatic [mCSCC] or locally advanced [laCSCC]) who are not candidates for curative surgery or radiation. Here, we present new longer-term follow-up data from the pivotal study. Methods: Pts with mCSCC (Group [Gp] 1) and laCSCC (Gp 2) were treated with cosibelimab 800 mg Q2W. The primary endpoint was objective response rate (ORR; complete response + partial response) by independent central review (ICR) assessed by Gp. The safety analysis included all CSCC pts treated with at least one dose and includes a third Gp of pts with mCSCC treated with cosibelimab 1200 mg Q3W (Gp 3). Results: As of the 31 March 2023 data cutoff, 192 pts were enrolled and treated (78 in Gp 1, 58 in Gp 2 and 56 in Gp 3), and 109 pts were eligible for long-term efficacy assessment (78 in Gp 1 and 31 in Gp 2). With a median duration of follow-up of 29.3 months (range: 0.4-52.0) for Gp 1 and 24.1 months (range: 2.8-37.3) for Gp 2, ORR per ICR was 50.0% (95% CI: 38.5-61.5) and 54.8% (95% CI: 36.0-72.7), respectively.The complete response rate was 12.8% and 25.8% for Gp 1 and 2, respectively. Median duration of response has not been reached in either Gp, with a probably of maintaining response at 24 months of 72.1% and 80.2% for Gp 1 and 2, respectively. The most common adverse events (AEs) by any grade (Gr) were fatigue (22.9%), anemia (20.3%), constipation (16.1%) and diarrhea (15.1%); Gr 3 were anemia (5.2%) and lipase increased (3.1%). 3.6% of pts experienced a Gr 3 immune-related AE (no Gr 4). Conclusions: Cosibelimab demonstrates robust objective response and complete response rates in advanced CSCC, with manageable safety and notable low rates of overall and severe immune-related AEs.Ye
Cyberbullying and Suicidal Behavior, Self-Harm, and Nonsuicidal Self-Injury: A Systematic Review of Longitudinal Studies.
No full textIdentify and systematically review cohort studies examining the association between cyberbullying (CB) and suicidal ideation, attempted suicide, self-harm, and nonsuicidal self-injury (NSSI). Systematic literature review following PRISMA guidelines. Searches for relevant literature were conducted in Scopus, Web of Science, PubMed, PsyINFO, CINAHL, Embase, and Cochrane up until July 2023. Cohort studies were included that provided information regarding the association between CB and different dimensions pertaining to self-injurious thoughts and behaviors (SITB) separately. Gathered information included data on study characteristics, sample characteristics, prevalence, and associations between CB and variables pertaining to SITB. Findings were synthesized, and grouping studies as a function of the outcome variable was analyzed. A total of 19 studies were included. Suicidal ideation was analyzed in 11 studies, with the majority ( = 8) reporting statistically significant positive associations (aOR = 1.88 [1.08, 3.29], β = 0.08 to 0.47). Only a single study conducted independent analysis of attempted suicide, finding a statistically significant association (aOR 1.88 [1.08, 3.29]). Outcomes regarding the self-harm variable were equivocal, with only two out of five studies finding a statistically significant association and one of these, which conducted a gender differentiated analysis, only finding a significant association in females. Studies that considered the NSSI dimension were also inconclusive, with only a limited number of studies ( = 5) producing contradictory outcomes. There is a need to continue exploring the relationship between CB and different dimensions within the spectrum of SITB through longitudinal studies. It is recommended that analyses adopt a new perspective in which short-term follow-up is prioritized or individualized follow-up periods are considered, given the rapidly changing nature of suicidal tendencies. It would be interesting to analyze the frequency, persistence, or severity of CB events and broaden research to include all age ranges. Special attention should also be given to potential gender differences and possible mediators or moderators.Ye
Vol. 29, nº 10. Predictores sociales y clínicos de colonización perianal por bacterias multirresistentes en pacientes geriátricos del servicio de medicina interna
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 09/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado ."Predictores sociales y clínicos de colonización perianal por bacterias multirresistentes en pacientes geriátricos del servicio de medicina interna”, de “María Del Carmen Valero-Ubierna, Alberto Benavente-Fernández, Javier Pérez de Rojas, Fidel Moreno-Verdejo, Jairo López-Gómez, Sergio Fernández-Ontiveros, Natalia Chueca-Porcuna, Cristina García-Marín, José Juan Jiménez-Moleón, Mario Rivera-Izquierdo”.Ye
Vol. 29, nº 32. Análisis de las pruebas PCR para Bordetella pertussis en el distrito sanitario Granada-metropolitano en periodo epidémico.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 31/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “Análisis de las pruebas PCR para Bordetella pertussis en el distrito sanitario Granada-metropolitano en periodo epidémico”, de “Cristina María García Blázquez Pérez., Adolfo de Salazar González, Basilio Gómez Pozo, Begoña López Hernández".Ye
Sex- and site-specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort.
No full textExperimental research has uncovered lipocalin 2 (LCN2) as a novel biomarker implicated in the modulation of intestinal inflammation, metabolic homeostasis, and colon carcinogenesis. However, evidence from human research has been scant. We, therefore, explored the association of pre-diagnostic circulating LCN2 concentrations with incident colorectal cancer (CRC) in a nested case-control study within the in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. LCN2 was measured in 1267 incident CRC cases matched to 1267 controls using incidence density sampling. Conditional logistic regression was used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) according to tumor subsite and sex. Weighted Cox proportional hazard regression was used to explore associations by adiposity status. In multivariable-adjusted analyses, the IRR [95% CI] per doubling in LCN2 concentration was 1.16 [0.98-1.37] for CRC overall, 1.26 [1.00-1.59] for colon cancer, and 1.08 [0.85-1.38] for rectal cancer. The association for colon cancer was more pronounced in women (IRR [95% CI], 1.66 [1.20-2.30]) and for proximal colon cancer (IRR [95% CI], 1.96 [1.15-3.34]), whereas no association was seen in men and distal colon cancer. The association for colon cancer was positive in individuals with high waist circumference (hazard ratio [95% CI], 1.69 [1.52-1.88]) and inverse in individuals with low waist circumference (hazard ratio [95% CI], 0.86 [0.76-0.98], P interaction<0.01). Overall, these data suggest that pre-diagnostic LCN2 concentrations were positively associated with colon cancer, particularly occurring in the proximal colon, in women and among individuals with abdominal adiposity.The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council, Region Skåne and Region Västerbotten (Sweden); Cancer Research UK (14,136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1,000,143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom).Ye